Dosing and uses of IBStat (hyoscyamine spray)
Adult dosage forms and strengths
oral spray
- 0.125 mg/mL (0.125 mg/spray)
Excessive Gastric Secretion
1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Other Indications & Uses
Peptic ulcer disease, abdominal cramps, spastic bladder, cystitis, pylorospasm, IBS, bilairy & renal colic, urinary incontinence, Parkinsonism, acute rhinitis, sialorrhea, hyperhidrosis, cholinergic poisoning
Heat prostration may be caused due to suppression of sweating
Pediatric dosage forms and strengths
oral spray
- 0.125 mg/mL (0.125 mg/spray)
Excessive Gastric Secretion
<12 years: Safety and efficacy not established
12 years or older: 1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Geriatric dosage forms and strengths
Avoid; high incidence of anticholinergic effects; avoid except in short-term situations to decrease secretions (Beers Criteria)
Excessive gastric secretion: 1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
IBStat (hyoscyamine spray) adverse (side) effects
Frequency not defined
Headache
Nervousness
Blurred vision
Cycloplegia/mydriasis
Increased IOp
Tachycardia
Urinary retention
Xerostomia
Warnings
Contraindications
Glaucoma, obstructive uropathy, GI obstruction, myasthenia gravis, toxic megacolon, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis
Cautions
Autonomic neuropathy, hiatal hernia, reflux esophagitis, renal dz, hyperthyroidism, tachyarrhythmia, CHF, salivary secretion disorder, BPH
Pregnancy and lactation
Pregnancy category: C
Lactation: excreted in breast milk, use caution (may suppress lactation)
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of IBStat (hyoscyamine spray)
Mechanism of action
Parasympatholytic, atropine-like effects, especially peripherally, blocks the action of ACh at parasympathetic sites in smooth muscle, secretory glands, and CNs
Pharmacokinetics
Absorption: rapid & complete
Half-Life: 2-3.5 hr
Protein Bound: 50%
Metabolism: Partially hydrolyzed to tropic acid & tropine
Excretion: Urine
Vd
- Adults: 1.2-1.9 L/kg
- Children 3.5-16 yo: 1.1-3.7 L/kg
